Immune Pharmaceuticals Inc. (NASDAQ:IMNP) dropped 5% during mid-day trading on Monday . The stock traded as low as $1.08 and last traded at $1.13. Approximately 538,102 shares changed hands during trading, a decline of 11% from the average daily volume of 602,657 shares. The stock had previously closed at $1.19.

The company’s market cap is $11.74 million. The stock has a 50 day moving average of $1.56 and a 200-day moving average of $1.78.

A hedge fund recently raised its stake in Immune Pharmaceuticals stock. Susquehanna International Group LLP raised its holdings in shares of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) by 41.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 69,805 shares of the biopharmaceutical company’s stock after acquiring an additional 20,488 shares during the quarter. Susquehanna International Group LLP owned approximately 0.69% of Immune Pharmaceuticals worth $215,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 4.36% of the company’s stock.

WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/13/immune-pharmaceuticals-inc-imnp-stock-price-down-5.html.

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.

Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.